Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 301–400 of 930
Optimal systemic therapy for high-risk resectable melanoma
Eggermont, A. M. M., Hamid, O., Long, G. V., & Luke, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00630-4 · Cited by 28
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
Conte, P., Dieci, M. V., Bisagni, G., Schmid, P., Zambelli, A., Piacentini, F., Laurentiis, M. D., Favaretto, A. G., Tamberi, S., Bianchi, G., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.005 · Cited by 26
Thaker, P. H., Bradley, W. H., Leath, C. A., Jackson, C. G., Borys, N., Anwer, K., Musso, L., Matsuzaki, J., Bshara, W., Odunsi, K. O., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0360 · Cited by 27
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 27
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 28
Wezel, F., Vallo, S., & Roghmann, F. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.09.18 · Cited by 28
Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Pelster, M. S., & Amaria, R. N. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0700-z · Cited by 29
Kok, M., Gielen, R.-J. C. A. M., Adams, S., Lennerz, J. K., Sharma, P., Loibl, S., Reardon, E. E., Sonke, G. S., Linn, S. C., Delaloge, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00372 · Cited by 26
Nie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.010 · Cited by 25
Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions
Rajan, A., Sivapiromrat, A. K., & McAdams, M. J. (2024) · Cancers · doi:10.3390/cancers16071369 · Cited by 25
“…of the anti-tumor immune response due to a higher tumor antigen load before resection, a greater chance of downstaging the tumor and increasing the chances of complete resection, early reversal of an immunosuppressed environment, and improved tolerability in treatment-naïve patients [69–71].”
BackgroundHaist, M., Stege, H. M., Kuske, M., Bauer, J., Klumpp, A., Grabbe, S., & Bros, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10097-z · Cited by 27
Advancing non-small cell lung cancer treatment: the power of combination immunotherapies
Wu, Y., Yu, G., Jin, K., & Qian, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349502 · Cited by 29
“Regarding the limited ef fi cacy of monotherapy using ICIs, preclinical research has revealed that neoadjuvant ICIs outperform adjuvant ICIs in eliminating distant metastases, owing to a sustained and intensi fi ed tumor-speci fi c immune response (109).”
MethodTang, S., Pan, H., Wei, W., Yang, H., Liu, J., & Yang, R. (2017) · Oncotarget · doi:10.18632/oncotarget.21927 · Cited by 25
Self-citationImmunological combination treatment holds the key to improving survival in pancreatic cancer
Sodergren, M. H., Mangal, N., Wasan, H. S., Sadanandam, A., Balachandran, V. P., Jiao, L. R., & Habib, N. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03332-5 · Cited by 28
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
Denkert, C., Schneeweiss, A., Rey, J., Karn, T., Hattesohl, A., Weber, K. E., Rachakonda, S., Braun, M., Huober, J., Jank, P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101825 · Cited by 25
Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond
Dallos, M. C., & Drake, C. G. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000302 · Cited by 27
The immunotherapeutic landscape in non–small cell lung cancer and its surgical horizons
Rhodin, K. E., Rucker, A. J., Ready, N., D’Amico, T. A., & Antonia, S. J. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.08.138 · Cited by 24
Ipilimumab: an investigational immunotherapy for glioblastoma
Youssef, G., & Dietrich, J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1826436 · Cited by 25
Ren, S., Xu, A., Lin, Y., Camidge, D. R., Maïo, M. D., Califano, R., Hida, T., Rossi, A., Guibert, N. M., Zhu, C., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-259 · Cited by 26
Zhao, M., Chen, S., Li, C., Du, Y., & Li, P. (2023) · Cancers · doi:10.3390/cancers15030600 · Cited by 25
“The investigators observed longer survival and enhanced activation of tumorspecific CD8+ T cells in mice administered PD-1 blockade preoperatively compared to mice receiving only postoperative treatment [45].”
BackgroundImmunotherapy in Melanoma: Recent Advancements and Future Directions
Mooradian, M. J., & Sullivan, R. J. (2023) · Cancers · doi:10.3390/cancers15164176 · Cited by 27
“Compelling pre-clinical data suggest that neoadjuvant immunotherapy, compared with adjuvant therapy alone, stimulates a more effective and diverse immune response, leading to the improved eradication of micrometastatic disease [83], with the SWOG1801 study establishing the benefit of peri-operative PD-1 inhibition ver…”
ResultRecent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
Yamashita, K., Matsuda, T., Hasegawa, H., Mukohyama, J., Arimoto, A., Tanaka, T., Yamamoto, M., Matsuda, Y., Kanaji, S., Nakamura, T., et al. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12213 · Cited by 24
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Huynh, C., Walsh, L. A., & Spicer, J. D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-509 · Cited by 25
Sun, X., Feng, Y., Zhang, B., Huang, W., Zhao, X., Zhang, H., Yue, D., & Wang, C. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.1007 · Cited by 24
A Darwinian perspective on tumor immune evasion
Puleo, J. I., & Polyák, K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188671 · Cited by 30
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
Burton, E. M., Milton, D. R., Tetzlaff, M. T., Wani, K., Ross, M. I., Postow, M. A., Lazcano, R., Oliva, I. C. G., Wong, M. K., Patel, S. P., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00494 · Cited by 23
Fallarino, F., & Blank, C. U. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01222-w · Cited by 27
“…metastatic breast cancer, the neoadjuvant combination of PD1 blockade plus activation of CD137, a co-stimulatory molecule that functions to promote T cell proliferation, dendritic cell maturation and B cell antibody secretion 97 , was highly effective, whereas the mono-therapies had no effect 22 .”
Radiotherapy and Immunotherapy Combinations for Lung Cancer
Agrawal, V., Benjamin, K. T., & Ko, E. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00993-w · Cited by 23
Peltonen, K., Feola, S., Umer, H. M., Chiaro, J., Mermelekas, G., Ylösmäki, E. O., Pesonen, S. A., Branca, R. M., Lehtiö, J., & Cerullo, V. (2021) · Cancers · doi:10.3390/cancers13143408 · Cited by 25
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
Chen, L. N., Wei, A. Z., & Shu, C. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163798 · Cited by 23
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
Chamseddine, S., LaPelusa, M. B., & Kaseb, A. O. (2023) · Cancers · doi:10.3390/cancers15133508 · Cited by 24
“Introducing immune checkpoint inhibitors in the neoadjuvant setting, where a larger tumor burden exists compared to the postoperative setting, can theoretically induce a stronger T-cell response, leading to a more profound antitumor effect [13].”
BackgroundSandbank, E., Eckerling, A., Margalit, A., Sorski, L., & Ben‐Eliyahu, S. (2023) · Current Oncology · doi:10.3390/curroncol30080540 · Cited by 24
“Preclinical studies in models of BC have found that neoadjuvant anti-CD25 mAbs therapy targeting regulatory T cells given 3 days before surgery was significantly more beneficial in extending survival outcomes than if given 3 days after surgery [98].”
BackgroundSuay, G., García‐Cañaveras, J. C., Aparisi, F., Lahoz, A., & Juan, Ó. (2023) · Cancers · doi:10.3390/cancers15184433 · Cited by 23
“The SAKK 16/14 study was a phase II trial that explored the neoadjuvant setting in stage IIIA-N2-positive patients with NSCLC [30].”
Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso, L., Ciardiello, D., Oliveira, R. A., Borghesani, M., Guidi, L., Benini, L., Algeri, L., Spada, F., Zampino, M. G., Cella, C. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008027 · Cited by 25
“21 This evidence was confirmed in the clinical setting: Blank et al 22 showed the improved effect of neoadjuvant administration immunotherapy compared with adjuvant immunotherapy in melanoma.”
BackgroundReview and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
Yi, C., He, Y., Xia, H., Zhang, H., & Zhang, P. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s218321 · Cited by 24
Brabo, E. P., Moraes, A. B., & Neto, L. V. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01306-5 · Cited by 25
Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response
Goode, E., Torres, E. T. R., & Irshad, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.674558 · Cited by 23
“This is in support of earlier data in murine models of metastatic breast cancer where neoadjuvant immunotherapy gave greater therapeutic efficacy compared with adjuvant treatment, and correlated with sustained peripheral anti-tumour immune responses (Liu et al., 2016).”
ResultUrakawa, S., Yamasaki, M., Makino, T., Kurokawa, Y., Yamamoto, K., Goto, K., Haruna, M., Hirata, M., Morimoto-Okazawa, A., Kawashima, A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02696-4 · Cited by 24
Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
Hu, Y. W., Ren, S.-Y., Wang, R.-Y., Zeng, C., Li, J., Xiao, P., Wu, F., Yu, F., & Liu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684070 · Cited by 23
“Furthermore, a preclinical study has confirmed that mice inoculated with metastatic breast cancer cells and treated with neoadjuvant anti-PD-1 have increased numbers of tumor-specific CD8+ T cells in the peripheral blood and organs, and they experience a longer survival period than their counterparts treated with adju…”
BackgroundChanzá, N. M., Soukane, L., Barthélémy, P., Carnot, A., Gil, T., Casert, V., Vanhaudenarde, V., Sautois, B. R., Staudacher, L., den Brande, J. V., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08990-3 · Cited by 23
Nguyen, V. P., Campbell, K. M., Nowicki, T. S., Elumalai, N., Medina, E., Baselga-Carretero, I., DiNome, M. L., Chang, H. R., Oseguera, D. K., Ribas, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0145 · Cited by 22
“Mouse models of spontaneous metastatic breast cancers have demonstrated a significantly greater therapeutic activity of neoadjuvant compared with adjuvant immune checkpoint blockade therapy (5).”
BackgroundThe Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
Liu, X., Dai, W., Zhao, Z., Liao, K., Sun, Q., Chen, D., Pan, X., Feng, L., Ding, Y., & Wei, S. (2023) · Cancers · doi:10.3390/cancers15174308 · Cited by 22
“This approach may prime an effective systemic immunity, potentially facilitating local lymphocyte infiltration while the tumor is surgically removed [96].”
BackgroundBiomarkers and experimental models for cancer immunology investigation
Xu, H., Jia, Z., Liu, F., Li, J., Huang, Y., Jiang, Y., Pu, P., Shang, T., Tang, P., Zhou, Y., et al. (2023) · MedComm · doi:10.1002/mco2.437 · Cited by 24
“338 As GEMMs initiate the neoplastic conversion of healthy cells within the appropriate organ site, the stepwise evolution and advancement of cancer enable the establishment of a multifaceted TME, encompassing both immunosuppressive conditions and stromal vasculature.”
BackgroundSelf-citationWiegand, S., Wichmann, G., & Dietz, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00191 · Cited by 22
“Inducing a systemic immune response just before surgery could not only activate effector CTL deleting tumor cells expressing tumor-associated antigens (TAA) but also lead to immunologic memory that may protect against tumor recurrence over a long time by eliminating neoplastic cells presenting TAA-derived peptides in…”
BackgroundInfluentialSaddawi‐Konefka, R., Simon, A. B., Sumner, W., Sharabi, A. B., Mell, L. K., & Cohen, E. E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738626 · Cited by 22
“found improved survival in a mouse model of triple negative breast cancer when checkpoint inhibition was initiated prior to rather than after surgical resection of the primary tumor (68).”
BackgroundExpert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Qiu, B., Cai, K., Chen, C., Chen, J., Chen, K., Chen, Q., Cheng, C., Dai, T., Fan, J., Fan, Z., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-634 · Cited by 22
Self-citationStravokefalou, V., Stellas, D., Karaliota, S., Nagy, B. A., Valentin, A., Bergamaschi, C., DIMAS, K. S., & Pavlakis, G. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1014802 · Cited by 26
“demonstrated that neoadjuvant immunotherapy is superior to adjuvant in controlling metastatic disease in two different murine models of TNBC (including the 4T1 model) (57).”
BackgroundHamy, A., Derosa, L., Valdelièvre, C., Yonekura, S., Opolon, P., Priour, M., Guerin, J., Pierga, J., Asselain, B. J. R., Croze, D. D., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1677427 · Cited by 22
Zhang, H., Chen, J., Bai, J., Zhang, J., Huang, S., Zeng, L., Zhou, P., Shen, Q., & Yin, T. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001226 · Cited by 23
“Evidence suggests that neoadjuvant therapy restores the local antitumor immune response, enhances systemic immunity, and eradicates residual metastasis more effectively in addition to being directly cytotoxic to cancer cells [6,7,9,10] .”
BackgroundGutiérrez, V., González, A. C., Gálvez, L., Lizarralde, Y. A., & Rueda‐Domínguez, A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920984061 · Cited by 23
Dai, J., Zhu, X., Li, D., Huang, Y. J., Liu, X., He, W., Duan, L., Zhao, D., Zhu, Y., Chen, C., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-56 · Cited by 22
Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
Marron, T. U., Schwartz, M., Corbett, V., & Mérad, M. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s340935 · Cited by 23
Li, R., Nocera, L., Rose, K. M., Raggi, D., Naidu, S. U., Mercinelli, C., Cigliola, A., Tateo, V., Patanè, D. A., Grass, G. D., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2023.12.008 · Cited by 22
Tumor inherent interferons: Impact on immune reactivity and immunotherapy
Brockwell, N. K., & Parker, B. S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.04.006 · Cited by 21
Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi, L., Yang, L., Wu, Z., Xu, W., Song, J. H., & Guan, W. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.023 · Cited by 22
Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy
Kuusk, T., Abu‐Ghanem, Y., Mumtaz, F., Powles, T. B., & Bex, A. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000868 · Cited by 21
“approach to eradicate distant micrometastases following primary tumour resection [18].”
BackgroundImmune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
Gust, K. M., Rebhan, K., Resch, I., Shariat, S. F., & Necchi, A. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000783 · Cited by 20
“Especially the mechanism of action of CPI favors their neoadjuvant use, as tumor-infiltrating lymphocytes and abundant tumor antigen are available for cross-priming at time of treatment and on the other site, T lymphocytes recirculated from the primary tumor may target microscopic metastatic disease [44].”
BackgroundNeoadjuvant immunotherapy in breast cancer: a paradigm shift?
Fountzila, E., & Ignatiadis, M. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1147 · Cited by 21
Zhang, X., Zhang, C., Hou, H., Zhang, Y., Jiang, P., Zhou, H., Wang, L., Zhou, N., & Zhang, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101657 · Cited by 20
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Chanzá, N. M., Tripathi, A., & Harshman, L. C. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0639-0 · Cited by 24
Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer
Chen, Y., Zhang, L., Yan, B., Zeng, Z., Hui, Z., Zhang, R., Ren, X., & You, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-539 · Cited by 20
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach
Versluis, J. M., Thommen, D. S., & Blank, C. U. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001352 · Cited by 21
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?
Bilušić, M., & Gulley, J. L. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa217 · Cited by 22
Neoadjuvant immune-checkpoint blockade in resectable colon cancer
Coukos, G. (2020) · Nature Medicine · doi:10.1038/s41591-020-0826-3 · Cited by 22
Pilard, C., Roncarati, P., Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Poulain, F., Bruyère, D., Lebeau, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010753 · Cited by 19
“69 70 Therefore, such a combination strategy should be favored in future clinical trials.”
Liu, S., Song, Y., Zhang, I. Y., Zhang, L., Gao, H., Su, Y., Yang, Y., Yin, S., Zheng, Y., Ren, L., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01207-w · Cited by 19
Emerging Targeted Therapies for Early Breast Cancer
Schlam, I. M., Tarantino, P., Morganti, S., Lynce, F. C., Trapani, D., Mayer, E. L., Garrido-Castro, A. C., Waks, A., & Tolaney, S. M. (2022) · Drugs · doi:10.1007/s40265-022-01781-5 · Cited by 19
Recent Advances in Perioperative Immunotherapies in Lung Cancer
Fukuda, S., Suda, K., Hamada, A., & Tsutani, Y. (2023) · Biomolecules · doi:10.3390/biom13091377 · Cited by 19
“In an in vivo study of mice with tumors derived from highly metastatic breast cancer cell lines, mice treated with neoadjuvant immunotherapy and surgical resection had longer survival than those treated with upfront surgery followed by adjuvant immunotherapy [18].”
BackgroundCunha, M. T., Gouveia, M. C., Neto, F. L., Testa, L., Hoff, P. M., de Azambuja, E., & Bonadio, R. C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02501-w · Cited by 19
Liu, X., Ji, Z., Zhang, L., Li, L., Xu, W., & Su, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13905-7 · Cited by 19
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development
Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 20
Synn, C., Kim, S. E., Lee, H. K., Kim, M. H., Kim, J. H., Lee, J. M., Jo, H.-N., Lee, W., Kim, D. K., Byeon, Y., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1364 · Cited by 20
Zhai, H., Li, W., Jiang, K., Zhi, Y., & Yang, Z. (2022) · Cancer Management and Research · doi:10.2147/cmar.s344343 · Cited by 21
“Recent thriving ICIs have reshaped the neoadjuvant treatments on the theoretical basis that they could induce a stronger adaptive antitumor response and release neoantigens from dying tumor cells before surgical resection.(22) The recent PACIFIC trial demonstrated the promising efficacy of durvalumab in combination wi…”
Tlr7 Agonist in Combination With Salmonella as an Effective Antimelanoma Immunotherapy
Vola, M., Mónaco, A., Bascuas, T., Rimsky, G., Agorio, C., Chabalgoity, J. A., & Moreno, M. (2018) · Immunotherapy · doi:10.2217/imt-2017-0188 · Cited by 21
Neoadjuvant immunotherapy in patients with resectable non–small cell lung cancer
Broderick, S., & Bott, M. J. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.06.114 · Cited by 20
Nelson, A., Krabbe, E., Björkström, K., Huibers, A. E., Jovanovic, B., Blank, C. U., Ullenhag, G. J., Helgadóttir, H., Ny, L., & Bagge, R. O. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115485 · Cited by 18
Schmid, D., Sobottka, B., Manzo, M., Trüb, M., Leonards, K., Herzig, P., Oyewole, O. R.-A., Jermann, P. M., Hayoz, S., Prince, S. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63696-5 · Cited by 18
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation
Bosi, C., Rimini, M., Gardini, A. C., & Ercolani, G. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2203387 · Cited by 18
Genomics and precision surgery for head and neck squamous cell carcinoma
Galmiche, A., Saidak, Z., Bouaoud, J., Mirghani, H., Page, C., Dakpé, S., & Clatot, F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.004 · Cited by 18
Catania, C., Muthusamy, B., Spitaleri, G., Signore, E. D., & Pennell, N. A. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.11.003 · Cited by 18
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
Davis, L., Tarduno, A., & Lu, Y. (2021) · Cancers · doi:10.3390/cancers13236061 · Cited by 19
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
Laschtowitz, A., Roderburg, C., Tacke, F., & Mohr, R. U. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s347944 · Cited by 18
“This concept has also been validated in animal models, where a preoperative PD-1 blockade led to improved survival and enhanced tumor-specific CD8+ T cell activation compared to postoperative PD-1 blockade.(18) Furthermore, it seems intuitive that surgical intervention with removal of lymph nodes may negatively affect…”
Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Puri, S., Shafique, M. R., & Gray, J. E. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0556-7 · Cited by 19
Abdel‐Aziz, A. K., Saadeldin, M. K., D’Amico, P., Orecchioni, S., Bertolini, F., Curigliano, G., & Minucci, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.013 · Cited by 18
Ren, S., Wang, C., Shen, J., & Zhu, C. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.44 · Cited by 19
Yang, Y., Wang, J., Zhang, T., Zhou, Z., Wang, Y., Jiang, Y., Liu, W., Xiao, Z., Deng, L., Feng, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1281888 · Cited by 17
David, T., Mallavialle, A., Faget, J., Alcaraz, L. B., Lapierre, M., du Roure, P. D., Laurent‐Matha, V., Mansouri, H., Jarlier, M., Martineau, P., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16291 · Cited by 18
“In mice harbouring E0771 cell-derived tumours, immunotherapy combining anti-PD1 and anti-CD137 antibodies increases the number of circulating CD8 + T, leading to enhanced antitumour response (Liu et al., 2016).”
van Akkooi, A. C. J., Mandalà, M., Nathan, P., Haydon, A. M., Postow, M. A., & Rutkowski, P. L. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100021 · Cited by 17
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
Bogatsa, E., Lazaridis, G., Stivanaki, C., & Timotheadou, E. T. (2024) · Cancers · doi:10.3390/cancers16091619 · Cited by 17
“…eradication of micrometastatic spreading alongside postoperative control of residual tumor burden further strengthens surgical results and may establish long-term regression-free outcomes, a hypothesis highlighted by a plethora of ongoing perioperative trials that have built on this rationale [22].”
BackgroundThe Emergence of Neoadjuvant Therapy in Advanced Melanoma
Sun, J. X., Kirichenko, D. A., Zager, J. S., & Eroglu, Z. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0007 · Cited by 18
Kris, M. G., Finn, C. F., Kordbacheh, T., Chaft, J. E., Luo, J., Tsao, A. S., & Swisher, S. G. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280807 · Cited by 17
Franco, A. O., Calvo, V., Franco, F., Provencio, M., & Califano, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-546 · Cited by 18
Tabakin, A. L., Stein, M. N., Anderson, C. B., Drake, C. G., & Singer, E. A. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2343 · Cited by 18
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
Ng, G. K. H., Xu, W., & Atkinson, V. G. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01288-y · Cited by 17
Majd, N., & de Groot, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1621840 · Cited by 17
Chen, B., Liu, S., Zhu, Y., Zhang, J., Bao, Y., Meng, F., Zhang, L., Cheng, X., Xuzhang, W., Chen, B., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-03044 · Cited by 16
Neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Xie, H., Shi, X., & Wang, G. (2021) · American Journal of Cancer Research · Cited by 16
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.